Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

A TREASURE TROVE OF SCIENCE

Multiple sclerosis (MS) is a disabling inflammatory, autoimmune demyelinating disease of the central nervous system. Despite intensive investigation, the mechanisms of disease pathogenesis remain unclear, and curative therapies are unavailable for MS. The current study describes a possible new strategy for the treatment of MS, based on the administration of the vasoactive intestinal peptide (VIP), a well-known immunosuppressive neuropeptide. Treatment with VIP significantly reduced incidence and severity of experimental autoimmune encephalomyelitis (EAE), in a MS-related rodent model system. VIP suppressed EAE neuropathology by reducing central nervous system inflammation, including the regulation of a wide spectrum of inflammatory mediators, and by selectively blocking encephalitogenic T-cell reactivity. Importantly, VIP treatment was therapeutically effective in established EAE and prevented the recurrence of the disease. Consequently, VIP represents a novel multistep therapeutic approach for the future treatment of human MS.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1606545/

The global multiple sclerosis drugs market size was valued at USD 25.00 billion in 2019 and is projected to reach USD 40.66 billion by 2027, exhibiting a CAGR of 7.1% during the forecast period.

https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386